Results 31 to 40 of about 72,295 (296)

Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases [PDF]

, 2011
We present six cases of patients with Japanese rheumatoid arthritis (RA) treated with a tumor necrosis factor (TNF)-alpha blocking agent, adalimumab as monotherapy for 220 weeks.
Shin-ya Kawashiri, Ida, Hiroaki, Kawakami, Atsushi, Makoto Kamachi, Kazuhiko Arima, Kamachi, Makoto, Iwamoto, Naoki, Hideki Nakamura, Tamai, Mami, Fujikawa, Keita, Tomoki Origuchi, Aramaki, Toshiyuki, Kawashiri, Shin-ya, Eguchi, Katsumi, Keita Fujikawa, Arima, Kazuhiko, Mami Tamai, Toshiyuki Aramaki, Katsumi Eguchi, Origuchi, Tomoki, Hiroaki Ida, Nakamura, Hideki, Atsushi Kawakami, Naoki Iwamoto, Ichinose, Kunihiro, Kunihiro Ichinose   +25 more
core   +1 more source

Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.

Gastroenterology, 2022
BACKGROUND & AIMS SERENE UC evaluated the efficacy of higher adalimumab induction and maintenance dose regimens in patients with ulcerative colitis (UC).
J. Panés, J. Colombel, G. D'Haens, S. Schreiber, R. Panaccione, L. Peyrin-Biroulet, E. Loftus, S. Danese, S. Tanida, Y. Okuyama, E. Louis, A. Armuzzi, M. Ferrante, H. Vogelsang, T. Hibi, M. Watanabe, J. Lefebvre, T. Finney-Hayward, Y. S. Gonzalez, T. Doan, N. Mostafa, Kimitoshi Ikeda, Wan-Gang Xie, Bidan Huang, J. Petersson, J. Kalabic, A. Robinson, W. Sandborn   +27 more
semanticscholar   +1 more source

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

Case Reports in Gastroenterology, 2019
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn’s
Taketo Suzuki, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshikazu Hirata, Yoshihide Kimura, Yuka Suzuki, Tomonori Yamada, Hironobu Tsukamoto, Takashi Mizushima, Naomi Sugimura, Takahito Katano, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki   +13 more
doaj   +1 more source

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

New England Journal of Medicine, 2019
BACKGROUND Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking.
B. Sands, L. Peyrin-Biroulet, E. Loftus, S. Danese, J. Colombel, M. Törüner, L. Jonaitis, B. Abhyankar, Jingjing Chen, Raquel Rogers, Richard A. Lirio, J. Bornstein, S. Schreiber   +12 more
semanticscholar   +1 more source

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

JAMA Surgery, 2021
This randomized clinical trial assesses the efficacy and safety of adalimumab in conjunction with surgery in adults with moderate to severe hidradenitis suppurativa.
F. Bechara, M. Podda, E. Prens, B. Horváth, E. Giamarellos-Bourboulis, A. Alavi, J. Szepietowski, J. Kirby, Z. Geng, C. Jean, G. Jemec, C. Zouboulis   +11 more
semanticscholar   +1 more source

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To evaluate the efficacy and safety of Secukinumab versus Adalimumab in the treatment of the moderate to severe plaque psoriasis. Methods A total of 90 patients with moderate to severe psoriasis were randomly divided into three groups ...
Dandan HU, Peimiao ZHANG
doaj   +1 more source

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.

New England Journal of Medicine, 2022
BACKGROUND The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis ...
J. Smolen, E. Feist, S. Fatenejad, S. Grishin, E. Korneva, E. Nasonov, M. Samsonov, R. Fleischmann   +7 more
semanticscholar   +1 more source

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients

Clinical and Translational Science, 2020
This study aimed at exploring the concentration‐effect relationship of adalimumab and early adalimumab and anti‐adalimumab antibody (AAA) levels in predicting primary nonresponse in a real‐world pilot cohort of patients with ankylosing spondylitis ...
Xiaoliang Ding, Ruifang Zhu, Jian Wu, Ling Xue, Meihua Gu, Liyan Miao   +5 more
doaj   +1 more source

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.

Inflammatory Bowel Diseases, 2022
BACKGROUND Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, and dose escalation may aid in regaining clinical benefit.
E. Savelkoul, P. Thomas, L. Derikx, N. den Broeder, T. Römkens, F. Hoentjen   +5 more
semanticscholar   +1 more source

Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan [PDF]

, 2016
Background: There are few reports of the efficacy of adalimumab (ADA) for clinical remission and preventing postoperative recurrence in Crohn's disease (CD) in Asian real practice settings.
Isomoto, Hajime, Hidetoshi Oda, Ken Ohnita, Fuminao Takeshima, Machida, Haruhisa, Oda, Hidetoshi, Hajime Isomoto, Morisaki, Tomohito, Ikeda, Maho, Matsushima, Kayoko, Akazawa, Yuko, Yoshikawa, Daisuke, Yamaguchi, Naoyuki, Syuntaro Higashi, Maho Ikeda, Masato Ueno, Nakao, Kazuhiko, Hitomi Minami, Kazuhiko Nakao, Tomohito Morisaki, Minami, Hitomi, Yuko Akazawa, Naoyuki Yamaguchi, Kayoko Matsushima, Takeshima, Fuminao, Higashi, Syuntaro, Haruhisa Machida, Ueno, Masato, Daisuke Yoshikawa, Ohnita, Ken   +29 more
core   +1 more source